

**Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb)  
Recombinant Antibody  
Catalog # APR10717****Specification**

---

**Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P35968</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.08 KDa

**Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) - Additional Information****Target/Specificity**  
VEGFR2 / KDR / CD309**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) - Protein Information****Name** KDR ([HGNC:6307](#))**Synonyms** FLK1, VEGFR2**Function**  
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA-

and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

#### Cellular Location

Cell junction. Endoplasmic reticulum. Cell membrane. Note=Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). {ECO:0000250, ECO:0000269|PubMed:23529610} [Isoform 2]: Secreted.

#### Tissue Location


Detected in cornea (at protein level). Widely expressed.

### Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) - Images



Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) on SDS-PAGE under reducing (R)

condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) is more than 95% ,determined by SEC-HPLC.